🇧🇪 UCB.BR — UCB SA

Salud Compra
← Volver

Precio actual

290,90 EUR

Máx. histórico

290,90

0 días

Caída desde máximo

En máximo

Rango 52 semanas

197,45 – 292,20

Variación hoy

+0,24%

Cierre anterior

290,20

Rango de hoy

279,10 – 291,20

Volumen hoy

260.813

Peor caída histórica

-66,30%

15/12/2006 → 27/10/2008

Recuperado en 1466 días

Volatilidad anualizada ⓘ

28,70%

Información
Nombre completo
UCB SA
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
9.000
PER ⓘ
25,70 (puede no estar actualizado)
Dividend yield
0,50% (puede no estar actualizado)
Precio objetivo analistas
291,58 EUR (puede no estar actualizado)
Primera cotización
04/01/2000
Precio actualizado
hace 1 día
Sobre la empresa

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Dividendos repartidos Total últimos 12 meses: 1,4500 EUR · Yield: 0,50%
Fecha de pago Importe por participación
04/05/2026 1,4500 EUR
25/04/2025 1,3900 EUR
26/04/2024 1,3600 EUR
28/04/2023 1,3300 EUR
29/04/2022 1,3000 EUR
30/04/2021 1,2700 EUR
04/05/2020 1,2400 EUR
26/04/2019 1,2100 EUR
27/04/2018 1,1800 EUR
28/04/2017 1,1500 EUR
29/04/2016 1,1000 EUR
04/05/2015 1,0600 EUR
29/04/2014 1,0400 EUR
02/05/2013 1,0200 EUR
27/04/2012 1,0000 EUR
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
13/02/2017 67,22 67,93 67,22 67,83 +0,56% 1,06% 207.005
10/02/2017 67,81 67,92 66,94 67,45 -0,49% 1,45% 284.913
09/02/2017 66,77 67,87 66,64 67,78 +1,70% 1,84% 438.153
08/02/2017 67,07 67,39 65,90 66,65 -0,82% 2,22% 282.460
07/02/2017 66,35 67,31 66,34 67,20 +1,02% 1,46% 379.436
06/02/2017 66,39 68,07 66,38 66,52 +0,03% 2,55% 429.489
03/02/2017 66,45 67,09 66,37 66,50 +0,27% 1,08% 400.157
02/02/2017 65,52 66,40 65,04 66,32 +1,04% 2,08% 352.349
01/02/2017 63,82 65,64 63,82 65,64 +3,01% 2,85% 436.268
31/01/2017 63,88 64,27 63,54 63,72 -0,47% 1,14% 346.520
30/01/2017 63,95 64,35 63,26 64,02 -0,11% 1,70% 187.369
27/01/2017 63,53 64,09 62,94 64,09 +0,77% 1,81% 216.120
26/01/2017 63,01 63,85 63,01 63,60 +1,00% 1,33% 195.247
25/01/2017 62,00 63,02 61,56 62,97 +1,56% 2,35% 396.191
24/01/2017 63,01 63,32 61,78 62,00 -1,76% 2,44% 251.460
23/01/2017 63,11 63,47 62,60 63,11 -0,30% 1,38% 196.888
20/01/2017 63,68 63,86 62,70 63,30 -0,44% 1,82% 416.371
19/01/2017 64,42 64,42 63,23 63,58 -1,38% 1,85% 298.915
18/01/2017 64,42 64,67 63,99 64,47 +0,26% 1,06% 213.456
17/01/2017 64,26 64,99 64,12 64,30 +0,08% 1,35% 295.725
16/01/2017 65,41 65,53 64,25 64,25 -1,76% 1,96% 259.708
13/01/2017 65,12 65,64 64,77 65,40 +1,49% 1,34% 249.688
12/01/2017 65,77 65,90 64,01 64,44 -2,53% 2,87% 343.525
11/01/2017 66,75 67,49 65,98 66,11 +1,07% 2,26% 364.784
10/01/2017 65,79 65,91 65,39 65,41 -0,38% 0,79% 216.627
09/01/2017 66,00 66,07 64,97 65,66 -0,32% 1,67% 225.971
06/01/2017 65,80 65,93 65,20 65,87 +0,47% 1,11% 242.697
05/01/2017 64,88 65,91 64,40 65,56 +1,91% 2,33% 379.108
04/01/2017 62,32 64,33 62,12 64,33 +3,74% 3,55% 380.135
03/01/2017 61,50 62,23 61,48 62,01 +1,21% 1,22% 267.500